OVERVIEW

Community Practice Connections™: The “Don't Crash” Crash Course in Managing Immune-Related Adverse Events (irAEs) in Oncology is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Given the importance of rapid assessment when a patient arrives in the emergency room, you need to have every tool available to provide a timely course of action. New therapies for cancer, such as immune checkpoint inhibitors (ICIs), have changed the field of oncology. These agents, however, can also lead to acute symptoms that can be life-threatening if not correctly diagnosed and managed. The “Don’t Crash” Crash Course in Managing Immune-Related Adverse Events in Oncology will provide you with knowledge about immune-related adverse events (irAEs), as well as optimal differential diagnostic and management strategies toward ensuring that patients can recover from irAEs and continue their cancer treatment.

This online educational activity features the Community Practice Connections™ platform, consisting of clinical vignettes and video clips featuring short expert interviews with oncologists and emergency department physicians who specialize in the diagnosis and management of irAEs experienced by patients undergoing immunotherapy for their cancer diagnosis. This activity consists of an overview on the mechanism of action of ICIs, which informs the etiology of irAEs. Through case-based scenarios, you will learn how to rapidly recognize and manage irAEs, such as colitis, pneumonitis, and thyroid dysfunction, in patients presenting in an emergency situation.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Recognize the mechanistic characteristics of checkpoint inhibitors in the context of the potential for immune-related adverse events (irAEs) with these agents
• Evaluate disease-related, comorbidity-related, and medication-related factors associated with an increased risk for, or impact of, specific types of irAEs
• Review potential irAEs, with an understanding of the relative frequency of specific types of irAEs, as well as best practices for toxicity management
• Develop evidence-based multidisciplinary approaches to promptly recognize and address potential irAEs associated with immune checkpoint inhibitors